This Article Full Text Full Text (PDF) Erratum (v18,p3877) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giuliano, A. E. Articles by Turner, R. R. Search for Related Content PubMed PubMed Citation Articles by Giuliano, A. E. Articles by Turner, R. R. Social Bookmarking                            What's this?

Prospective Observational Study of Sentinel Lymphadenectomy Without Further Axillary Dissection in Patients With Sentinel Node–Negative Breast Cancer

From the Joyce Eisenberg-Keefer Breast Center, Division of Surgical Oncology, Statistical Coordinating Unit, Department of Nuclear Medicine, and Department of Pathology, John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, CA.

Address reprint requests to Armando E. Giuliano, MD, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404; email giulianoa{at}jwci.org

PURPOSE: Immediate complete axillary lymphadenectomy (ALND) after sentinel lymphadenectomy (SLND) has confirmed that tumor-negative sentinel nodes accurately predict tumor-free axillary nodes in breast cancer. Therefore, we hypothesized that SLND alone in patients with tumor-negative sentinel nodes would achieve axillary control, with minimal complications.

PATIENTS AND METHODS: Between October 1995 and July 1997, 133 consecutive women who had primary invasive breast tumors clinically 4 cm in diameter and no axillary lymphadenopathy were prospectively entered onto a trial of SLND using vital blue dye. Sentinel nodes were examined by standard microscopy or immunohistochemistry. SLND was the only axillary surgery if sentinel nodes were tumor-free. Completion ALND was performed only if sentinel nodes contained metastases or if they were not identified. Excluded from subsequent analysis were patients with unsuspected multifocal carcinoma and those who refused completion ALND. The complication and axillary recurrence rates after SLND without ALND were determined.

RESULTS: Sentinel nodes were identified in 132 (99%) of 133 patients. Eight patients were excluded from further analysis. Of the 125 assessable patients, 57 had tumor-positive sentinel nodes and one had an unsuccessful mapping procedure; these patients underwent completion ALND. In the remaining 67 patients (54%), SLND was the only axillary procedure. Complications occurred in 20 patients (35%) undergoing ALND after SLND but in only two patients (3%) undergoing SLND alone (P = .001). There were no local or axillary recurrences at a median follow-up of 39 months.

CONCLUSION: Complication rates are negligible after SLND alone. An absence of axillary recurrences supports SLND as an accurate staging alternative for breast cancer and suggests that routine ALND can be eliminated for patients with histopathologically negative sentinel nodes.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Canavese, A. Catturich, C. Vecchio, D. Tomei, M. Gipponi, G. Villa, F. Carli, P. Bruzzi, and B. Dozin Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial Ann. Onc., June 1, 2009; 20(6): 1001 - 1007. [Abstract] [Full Text] [PDF]

				P. Poletti, P. Fenaroli, A. Milesi, A. Paludetti, S. Mangiarotti, G. Virotta, E. Candiago, A. Bettini, E. R. Caremoli, R. Labianca, et al. Axillary recurrence in sentinel lymph node-negative breast cancer patients Ann. Onc., November 1, 2008; 19(11): 1842 - 1846. [Abstract] [Full Text] [PDF]

				D. P. Cronin-Fenton, L. A. Ries, L. X. Clegg, and B. K. Edwards Rising Incidence Rates of Breast Carcinoma With Micrometastatic Lymph Node Involvement J Natl Cancer Inst, July 4, 2007; 99(13): 1044 - 1049. [Abstract] [Full Text] [PDF]

				Y A Masannat, A M Shaaban, V Speirs, G Coast, P Jackson, K Horgan, and A M Hanby Adverse effects of dyes used in sentinel node biopsy on immunocytochemical determination of hormone receptors in breast cancer cells J. Clin. Pathol., June 1, 2007; 60(6): 730 - 732. [Full Text] [PDF]

				L. A. Newman The Komen Foundation: ACS Outreach Collaboration--Sentinel Lymph Node Biopsy Training for Practicing Surgeons in Remote or Underserved Communities J. Oncol. Pract, November 1, 2006; 2(6): 285 - 287. [Full Text] [PDF]

				R. E. Mansel, L. Fallowfield, M. Kissin, A. Goyal, R. G. Newcombe, J. M. Dixon, C. Yiangou, K. Horgan, N. Bundred, I. Monypenny, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst, May 3, 2006; 98(9): 599 - 609. [Abstract] [Full Text] [PDF]

				G. Houvenaeghel, C. Nos, H. Mignotte, J. M. Classe, S. Giard, P. Rouanet, F. P. Lorca, J. Jacquemier, and V. J. Bardou Micrometastases in Sentinel Lymph Node in a Multicentric Study: Predictive Factors of Nonsentinel Lymph Node Involvement--Groupe Des Chirurgiens De La Federation Des Centres De Lutte Contre Le Cancer J. Clin. Oncol., April 20, 2006; 24(12): 1814 - 1822. [Abstract] [Full Text] [PDF]

				G. Falconieri, S. Pizzolitto, and G. Gentile Comprehensive Examination of Sentinel Lymph Node in Breast Cancer: A Solution Without a Problem? International Journal of Surgical Pathology, January 1, 2006; 14(1): 1 - 8. [Abstract] [PDF]

				L. A. Newman Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer Patients J. Oncol. Pract, November 1, 2005; 1(4): 130 - 133. [Full Text] [PDF]

				R. M. Morrell, M. Y. Halyard, S. E. Schild, M. S. Ali, L. L. Gunderson, and B. A. Pockaj Breast Cancer-Related Lymphedema Mayo Clin. Proc., November 1, 2005; 80(11): 1480 - 1484. [Abstract] [PDF]

				G. H. Lyman, A. E. Giuliano, M. R. Somerfield, A. B. Benson III, D. C. Bodurka, H. J. Burstein, A. J. Cochran, H. S. Cody III, S. B. Edge, S. Galper, et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer J. Clin. Oncol., October 20, 2005; 23(30): 7703 - 7720. [Abstract] [Full Text] [PDF]

				A. D. Purushotham, S. Upponi, M. B. Klevesath, L. Bobrow, K. Millar, J. P. Myles, and S. W. Duffy Morbidity After Sentinel Lymph Node Biopsy in Primary Breast Cancer: Results From a Randomized Controlled Trial J. Clin. Oncol., July 1, 2005; 23(19): 4312 - 4321. [Abstract] [Full Text] [PDF]

				M. Shinozaki, D. S.B. Hoon, A. E. Giuliano, N. M. Hansen, H.-J. Wang, R. Turner, and B. Taback Distinct Hypermethylation Profile of Primary Breast Cancer Is Associated with Sentinel Lymph Node Metastasis Clin. Cancer Res., March 15, 2005; 11(6): 2156 - 2162. [Abstract] [Full Text] [PDF]

				E. P. Mamounas Continuing Evolution in Breast Cancer Surgical Management J. Clin. Oncol., March 10, 2005; 23(8): 1603 - 1606. [Full Text] [PDF]

				W E Mesker, H Torrenga, W C R Sloos, H Vrolijk, R A E M Tollenaar, P C de Bruin, P J van Diest, and H J Tanke Supervised automated microscopy increases sensitivity and efficiency of detection of sentinel node micrometastases in patients with breast cancer J. Clin. Pathol., September 1, 2004; 57(9): 960 - 964. [Abstract] [Full Text] [PDF]

				N Lamichhane, K W Shen, C L Li, Q X Han, Y J Zhang, Z M Shao, and Z Z Shen Sentinel lymph node biopsy in breast cancer patients after overnight migration of radiolabelled sulphur colloid Postgrad. Med. J., September 1, 2004; 80(947): 546 - 550. [Abstract] [Full Text] [PDF]

				K. Suga, Y. Yuan, M. Okada, N. Matsunaga, A. Tangoku, S. Yamamoto, and M. Oka Breast Sentinel Lymph Node Mapping at CT Lymphography with Iopamidol: Preliminary Experience Radiology, February 1, 2004; 230(2): 543 - 552. [Abstract] [Full Text] [PDF]

				S. B. Edge, J. C. Niland, M. A. Bookman, R. L. Theriault, R. Ottesen, E. Lepisto, and J. C. Weeks Emergence of Sentinel Node Biopsy in Breast Cancer as Standard-of-Care in Academic Comprehensive Cancer Centers J Natl Cancer Inst, October 15, 2003; 95(20): 1514 - 1521. [Abstract] [Full Text] [PDF]

				D. K. Blanchard, J. H. Donohue, C. Reynolds, and C. S. Grant Relapse and Morbidity in Patients Undergoing Sentinel Lymph Node Biopsy Alone or With Axillary Dissection for Breast Cancer Arch Surg, May 1, 2003; 138(5): 482 - 488. [Abstract] [Full Text] [PDF]

				J. Bonnema and C. J. H. van de Velde Sentinel lymph node biopsy in breast cancer Ann. Onc., October 1, 2002; 13(10): 1531 - 1537. [Abstract] [Full Text] [PDF]

				B. Taback, K. Hashimoto, C. T. Kuo, A. Chan, A. E. Giuliano, and D. S. B. Hoon Molecular Lymphatic Mapping of the Sentinel Lymph Node Am. J. Pathol., October 1, 2002; 161(4): 1153 - 1161. [Abstract] [Full Text] [PDF]

				N. M. Hansen, B. J. Grube, and A. E. Giuliano The Time Has Come to Change the Algorithm for the Surgical Management of Early Breast Cancer Arch Surg, October 1, 2002; 137(10): 1131 - 1135. [Abstract] [Full Text] [PDF]

				M. Morrow and W. Gradishar Recent developments: Breast cancer BMJ, February 16, 2002; 324(7334): 410 - 414. [Full Text] [PDF]

				P J Ell A revolution in surgical oncology: sentinel lymph node biopsy Imaging, September 1, 2001; 13(3): 197 - 205. [Abstract] [Full Text] [PDF]

				G. Mariani, L. Moresco, G. Viale, G. Villa, M. Bagnasco, G. Canavese, J. Buscombe, H. W. Strauss, and G. Paganelli Radioguided Sentinel Lymph Node Biopsy in Breast Cancer Surgery J. Nucl. Med., August 1, 2001; 42(8): 1198 - 1215. [Abstract] [Full Text] [PDF]

				R. J. Rosser, A. Giuliano, and K. McMasters Safety of Sentinel Lymph Node Dissection and Significance of Cytokeratin Micrometastases J. Clin. Oncol., March 15, 2001; 19(6): 1882 - 1883. [Full Text]

				D. Krag, T. Ashikaga, J. Abrams, and A. E. Giuliano Sentinel Nodes: Clinical Trial Data Needed J. Clin. Oncol., November 15, 2000; 18(22): 3873 - 3874. [Full Text] [PDF]